Published in Cancer Res on May 01, 2005
Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. Nat Cell Biol (2012) 3.03
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol (2007) 2.24
Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol (2010) 2.13
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer (2009) 1.34
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol (2011) 1.34
Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta (2013) 1.27
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol Cancer Ther (2008) 1.26
Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5. Autophagy (2012) 1.16
Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther (2013) 1.15
The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer (2008) 1.12
Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines. PLoS One (2012) 1.03
Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer (2008) 1.03
DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity. Radiat Oncol (2012) 1.02
The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother Pharmacol (2010) 0.99
Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors. Virol J (2011) 0.92
Effects of mood stabilizers on DNA damage in an animal model of mania. J Psychiatry Neurosci (2008) 0.88
Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents. J Pharmacol Exp Ther (2012) 0.87
HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells. Cell Death Differ (2012) 0.87
Histone deacetylase classes I and II regulate Kaposi's sarcoma-associated herpesvirus reactivation. J Virol (2013) 0.87
Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model. Carcinogenesis (2009) 0.86
Valproic acid suppresses Nrf2/Keap1 dependent antioxidant protection through induction of endoplasmic reticulum stress and Keap1 promoter DNA demethylation in human lens epithelial cells. Exp Eye Res (2014) 0.85
Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis Study. Medicine (Baltimore) (2016) 0.85
Interpreting clinical assays for histone deacetylase inhibitors. Cancer Manag Res (2011) 0.85
Chromatin and lamin A determine two different mechanical response regimes of the cell nucleus. Mol Biol Cell (2017) 0.84
Valproic acid affects membrane trafficking and cell-wall integrity in fission yeast. Genetics (2007) 0.84
Chromatin remodeling, cell proliferation and cell death in valproic acid-treated HeLa cells. PLoS One (2011) 0.83
Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLoS One (2012) 0.82
Multiple pathways regulating the anti-apoptotic protein clusterin in breast cancer. Biochim Biophys Acta (2007) 0.82
Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neuro Oncol (2011) 0.82
A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma. J Cell Biochem (2012) 0.81
Valproic acid silencing of ascl1b/Ascl1 results in the failure of serotonergic differentiation in a zebrafish model of fetal valproate syndrome. Dis Model Mech (2013) 0.81
Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium. Neurobiol Aging (2007) 0.81
CHD2 myoclonic encephalopathy is frequently associated with self-induced seizures. Neurology (2015) 0.80
Fractal Characterization of Chromatin Decompaction in Live Cells. Biophys J (2015) 0.80
Development to term of cloned cattle derived from donor cells treated with valproic acid. PLoS One (2014) 0.79
HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo. Genet Vaccines Ther (2007) 0.79
Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise? Front Oncol (2014) 0.78
Processing of DNA double strand breaks by alternative non-homologous end-joining in hyperacetylated chromatin. Genome Integr (2012) 0.77
Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells. Interdiscip Toxicol (2009) 0.77
DNA and histone deacetylases as targets for neuroblastoma treatment. Interdiscip Toxicol (2010) 0.77
The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death. Am J Transl Res (2013) 0.77
Network Reconstruction Reveals that Valproic Acid Activates Neurogenic Transcriptional Programs in Adult Brain Following Traumatic Injury. Pharm Res (2017) 0.76
Generation of human induced pluripotent stem cells using epigenetic regulators reveals a germ cell-like identity in partially reprogrammed colonies. PLoS One (2013) 0.76
Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA). Int J Clin Exp Pathol (2015) 0.76
Sodium valproate inhibits the growth of human cholangiocarcinoma in vitro and in vivo. Gastroenterol Res Pract (2013) 0.76
Novel method to ascertain chromatin accessibility at specific genomic loci from frozen brain homogenates and laser capture microdissected defined cells. Neuroepigenetics (2016) 0.75
Effect of sodium valproate on the toxicity of cyclophosphamide in the testes of mice: influence of pre- and post-treatment schedule. Toxicol Int (2013) 0.75
Reprogramming the cardiac field. Circ Res (2014) 0.75
Extrachromosomal HPV-16 LCR transcriptional activation by HDACi opposed by cellular differentiation and DNA integration. Oncotarget (2016) 0.75
DNA Methylation Changes in Valproic Acid-Treated HeLa Cells as Assessed by Image Analysis, Immunofluorescence and Vibrational Microspectroscopy. PLoS One (2017) 0.75
Effects of Valproic Acid on Radiation-Induced Chromosomal Aberrations in Human Lymphocytes. Genome Integr (2017) 0.75
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma. Eur J Clin Pharmacol (2016) 0.75
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol (2008) 2.88
Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol (2011) 2.43
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol (2007) 2.39
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol (2008) 2.35
Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene (2002) 2.34
Removing the unknown from the carcinoma of unknown primary. J Clin Oncol (2012) 1.99
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A (2013) 1.88
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res (2009) 1.79
Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood (2007) 1.65
CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem (2008) 1.65
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2011) 1.52
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem (2004) 1.43
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res (2009) 1.42
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol (2011) 1.34
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control (2007) 1.32
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res (2007) 1.32
Fatigue after treatment for early stage breast cancer: a controlled comparison. Cancer (2007) 1.28
ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood (2006) 1.27
Identifying clinically meaningful fatigue with the Fatigue Symptom Inventory. J Pain Symptom Manage (2008) 1.21
FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol (2007) 1.20
Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer (2009) 1.20
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol (2014) 1.20
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res (2011) 1.17
Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control (2003) 1.17
Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs (2010) 1.16
Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther (2013) 1.15
Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr (2011) 1.15
Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res (2009) 1.12
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther (2005) 1.11
Activated stat-3 in melanoma. Cancer Control (2008) 1.11
Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet (2011) 1.10
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther (2009) 1.09
Co-evolving motions at protein-protein interfaces of two-component signaling systems identified by covariance analysis. Biochemistry (2008) 1.06
Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett (2009) 1.04
T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun (2007) 1.03
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res (2013) 1.03
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res (2009) 1.02
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res (2011) 1.02
The 2010 Health Care Reform Act: a potential opportunity to advance cancer research by taking cancer personally. Clin Cancer Res (2010) 1.01
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res (2008) 1.01
Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res (2010) 1.01
Exploring the differential experience of breast cancer treatment-related symptoms: a cluster analytic approach. Support Care Cancer (2007) 1.00
Human topoisomerase IIalpha nuclear export is mediated by two CRM-1-dependent nuclear export signals. J Cell Sci (2004) 0.99
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst (2013) 0.99
The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells. Exp Cell Res (2004) 0.97
Uncommon manifestations of common malignancies: case 3. Malignant melanoma arising from a spinal nerve root. J Clin Oncol (2004) 0.97
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res (2011) 0.95
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res (2005) 0.94
CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo. J Cancer (2013) 0.94
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res (2009) 0.94
Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect. Mol Cancer Ther (2010) 0.93
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol (2003) 0.92
Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control (2006) 0.92
Physical symptoms/side effects during breast cancer treatment predict posttreatment distress. Ann Behav Med (2007) 0.92
Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 0.90
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest (2016) 0.89
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res (2007) 0.89
BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J Gynecol Oncol (2012) 0.89
New protein kinase inhibitors in breast cancer: afatinib and neratinib. Expert Opin Pharmacother (2014) 0.87
Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma. Cell Oncol (Dordr) (2011) 0.87
Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol (2014) 0.86
Measurement of multisite oxidation kinetics reveals an active site conformational change in Spo0F as a result of protein oxidation. Biochemistry (2006) 0.86
An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second 'primary' tumor. J Cutan Pathol (2011) 0.85
Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Epigenomics (2011) 0.85
A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep (2013) 0.85
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety. Cancer Chemother Pharmacol (2007) 0.85
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res (2015) 0.84
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res (2006) 0.84
The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecol Oncol (2011) 0.84
Immunotherapy as part of a multidisciplinary approach to melanoma treatment. Front Biosci (2006) 0.84
Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol (2014) 0.83
Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res (2011) 0.83
Tumor p53 status and response to topoisomerase II inhibitors. Drug Resist Updat (2003) 0.82
Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. Int J Gynecol Cancer (2012) 0.82
Rapid screening of novel agents for combination therapy in sarcomas. Sarcoma (2013) 0.81
Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt. PLoS One (2013) 0.81
State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer. Cancer (2008) 0.80